{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:58:14Z","timestamp":1790693894463,"version":"4.1.0"},"reference-count":65,"publisher":"Bioscientifica","issue":"9","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuroendocrine neoplasms (NENs) are a diverse group of rare cancers with high heritability and limited treatment options for metastatic disease. Genomic testing guidelines for patients with NENs are limited to germline testing in high-risk individuals and tumour mutational burden (TMB) in a subset of patients. Here, we assess the prevalence of clinically actionable somatic variants using gene panel testing in the AACR GENIE database, and our real-world experience using additional genomic testing methodologies such as whole genome sequencing (WGS) and circulating tumour DNA sequencing for patients with NENs. The AACR GENIE database contained large panel data for 2,838 samples representing 26 different NEN subtypes. Of the samples, 19.1% had an OncoKB-defined actionable variant; however, only 1.6% were Level 1. TMB \u2265 10 mut\/Mb was found in 21% of the assessable AACR GENIE cohort, mostly in NEC subtypes. Our institutional cohort of 30 patients was analysed using tumour-normal WGS in 24\/33 testing episodes. Eight of thirty patients (27%) had variant-based clinical trial recommendations made. Seven of twenty-four WGS cases (29%) had clinically reportable germline variants identified. Circulating tumour DNA testing (n = 5\/33) was used to sequence patients with uncontrolled hormone syndromes and when adequate tissue was not available. In selected patients with certain metastatic NET subtypes or NECs, our data support consideration of comprehensive tumour-normal genomic testing.<\/jats:p>","DOI":"10.1530\/erc-26-0225","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:59:22Z","timestamp":1790690362000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic and therapeutic impact of genomic testing in neuroendocrine neoplasms"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7631-9147","authenticated-orcid":true,"given":"Emma","family":"Boehm","sequence":"first","affiliation":[{"name":"Department of Clinical Pathology, The University of Melbourne 1 , , ,","place":["Melbourne, Victoria, Australia"]},{"name":"Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne 2 , , ,","place":["Melbourne, Victoria, Australia"]},{"name":"Neuroendocrine Tumour Centre of Excellence, Peter MacCallum Cancer Centre 3 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Flynn","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, The University of Melbourne 1 , , ,","place":["Melbourne, Victoria, Australia"]},{"name":"Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne 2 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Fai","family":"Nip","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Centre of Excellence, Peter MacCallum Cancer Centre 3 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Varghese","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne 2 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Nicolson","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne 2 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Balachander","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne 2 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0272-872X","authenticated-orcid":true,"given":"Camilla B","family":"Thornton","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne 2 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chan","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne 2 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying (Layla)","family":"Zhu","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne 2 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Rebello","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, The University of Melbourne 1 , , ,","place":["Melbourne, Victoria, Australia"]},{"name":"Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne 2 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah-Jane","family":"Dawson","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne 4 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J","family":"Hicks","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Department of Medicine, University of Melbourne 5 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael KC","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre 6 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J","family":"Solomon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre 6 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Li","family":"Wong","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne 4 , , ,","place":["Melbourne, Victoria, Australia"]},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre 6 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison H","family":"Trainer","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne 4 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1545-0368","authenticated-orcid":true,"given":"Roderick","family":"Clifton-Bligh","sequence":"additional","affiliation":[{"name":"Cancer Genetics Laboratory, Kolling Institute, University of Sydney 7 , , ,","place":["St Leonards, New South Wales, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kong","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Centre of Excellence, Peter MacCallum Cancer Centre 3 , , ,","place":["Melbourne, Victoria, Australia"]},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne 4 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Michael","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Centre of Excellence, Peter MacCallum Cancer Centre 3 , , ,","place":["Melbourne, Victoria, Australia"]},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne 4 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph HA","family":"Vissers","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne 2 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Luen","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne 4 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M","family":"Grimmond","sequence":"additional","affiliation":[{"name":"Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne 2 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W","family":"Tothill","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, The University of Melbourne 1 , , ,","place":["Melbourne, Victoria, Australia"]},{"name":"Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne 2 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026092909590533400_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026092909590533400_bib2","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in neuroendocrine tumors","volume":"139","author":"Riihim\u00e4ki","year":"2016","journal-title":"Int J Cancer"},{"key":"2026092909590533400_bib3","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/cam4.1507","article-title":"Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study","volume":"7","author":"Cai","year":"2018","journal-title":"Cancer Med"},{"key":"2026092909590533400_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11912-023-01381-w","article-title":"Integrating functional imaging and molecular profiling for optimal treatment selection in neuroendocrine neoplasms (NEN)","volume":"25","author":"Kong","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"2026092909590533400_bib5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026092909590533400_bib6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"key":"2026092909590533400_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13073-021-00969-w","article-title":"Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-na\u00efve study","volume":"13","author":"Sicklick","year":"2021","journal-title":"Genome Med"},{"key":"2026092909590533400_bib8","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1038\/s41467-021-24812-3","article-title":"The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets","volume":"12","author":"van Riet","year":"2021","journal-title":"Nat Commun"},{"key":"2026092909590533400_bib9","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/cen.14639","article-title":"Investigating the role of somatic sequencing platforms for phaeochromocytoma and paraganglioma in a large UK cohort","volume":"97","author":"Winzeler","year":"2022","journal-title":"Clin Endocrinol"},{"key":"2026092909590533400_bib10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3390\/cancers14051119","article-title":"Update on epidemiology, diagnosis, and biomarkers in gastroenteropancreatic neuroendocrine neoplasms","volume":"14","author":"Takayanagi","year":"2022","journal-title":"Cancers"},{"key":"2026092909590533400_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2023.03.024","article-title":"Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data","volume":"186","author":"Boil\u00e8ve","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026092909590533400_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13099","article-title":"Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms","volume":"34","author":"Taboada","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"2026092909590533400_bib13","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0292","article-title":"Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms","volume":"31","author":"Cowzer","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"2026092909590533400_bib14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3390\/cancers14041017","article-title":"Molecular profiling of well-differentiated neuroendocrine tumours: the role of ctDNA in real-world practice","volume":"14","author":"Lamarca","year":"2022","journal-title":"Cancers"},{"key":"2026092909590533400_bib15","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1210\/clinem\/dgae283","article-title":"Clinical activity of selpercatinib in RET-mutant pheochromocytoma","volume":"110","author":"Deschler-Baier","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092909590533400_bib16","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/PO.21.00127","article-title":"Novel RET fusion RET-SEPTIN9 predicts response to selective RET inhibition with selpercatinib in malignant pheochromocytoma","volume":"5","author":"Mweempwa","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2026092909590533400_bib17","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-20-1630","article-title":"US phase I first-in-human study of Taletrectinib (DS-6051b\/AB-106), a ROS1\/TRK inhibitor, in patients with advanced solid tumors","volume":"26","author":"Papadopoulos","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026092909590533400_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.911294","article-title":"Targeting ALK in neuroendocrine tumors of the lung","volume":"12","author":"Akhoundova","year":"2022","journal-title":"Front Oncol"},{"key":"2026092909590533400_bib19","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026092909590533400_bib20","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"2026092909590533400_bib21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2026092909590533400_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13249","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma","volume":"35","author":"Sorbye","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2026092909590533400_bib23","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: Powering precision medicine through an International Consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov"},{"key":"2026092909590533400_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13073-018-0531-8","article-title":"Cancer genome interpreter annotates the biological and clinical relevance of tumor alterations","volume":"10","author":"Tamborero","year":"2018","journal-title":"Genome Med"},{"key":"2026092909590533400_bib25","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2026092909590533400_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the expanding landscape of clinical actionability for patients with cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov"},{"key":"2026092909590533400_bib27","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"key":"2026092909590533400_bib28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"key":"2026092909590533400_bib29","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat Commun"},{"key":"2026092909590533400_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-018-0539-0","article-title":"Mutational patterns: comprehensive genome-wide analysis of mutational processes","volume":"10","author":"Blokzijl","year":"2018","journal-title":"Genome Med"},{"key":"2026092909590533400_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"key":"2026092909590533400_bib32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"2026092909590533400_bib33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2026092909590533400_bib34","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/humu.23645","article-title":"ClinGen variant curation expert panel experiences and standardized processes for disease and gene-level specification of the ACMG\/AMP guidelines for sequence variant interpretation","volume":"39","author":"Rivera-Mu\u00f1oz","year":"2018","journal-title":"Hum Mutat"},{"key":"2026092909590533400_bib35","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/2159-8290.CD-21-0669","article-title":"Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system","volume":"12","author":"Yachida","year":"2022","journal-title":"Cancer Discov"},{"key":"2026092909590533400_bib36","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1158\/1078-0432.CCR-20-1804","article-title":"Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)","volume":"26","author":"Puccini","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026092909590533400_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41698-025-01210-2","article-title":"CDKN2A homozygous deletions and TSC2 somatic mutations in metastatic pancreatic neuroendocrine tumors","volume":"10","author":"Jesus","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026092909590533400_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI Insight"},{"key":"2026092909590533400_bib39","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1038\/s41467-019-11276-9","article-title":"Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids","volume":"10","author":"Alcala","year":"2019","journal-title":"Nat Commun"},{"key":"2026092909590533400_bib40","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1038\/s41467-025-59661-x","article-title":"Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary","volume":"16","author":"Rebello","year":"2025","journal-title":"Nat Commun"},{"key":"2026092909590533400_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-025-01534-5","article-title":"Pathologist-initiated whole genome and transcriptome sequencing demonstrates diagnostic utility in resolving difficult-to-diagnose tumors","volume":"17","author":"Vissers","year":"2025","journal-title":"Genome Med"},{"key":"2026092909590533400_bib42","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1158\/0008-5472.CAN-15-1877","article-title":"UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas","volume":"75","author":"Wong","year":"2015","journal-title":"Cancer Res"},{"key":"2026092909590533400_bib43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cancergencyto.2003.10.013","article-title":"Chromosome 11 monosomy in conjunction with a mutated SDHD initiation codon in nonfamilial paraganglioma cases","volume":"150","author":"Riemann","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"2026092909590533400_bib44","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"2026092909590533400_bib45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2026092909590533400_bib46","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","article-title":"False-positive plasma genotyping due to clonal hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026092909590533400_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-21-0152","article-title":"The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Venizelos","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"2026092909590533400_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026092909590533400_bib49","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12328-022-01599-4","article-title":"Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma","volume":"15","author":"Nakano","year":"2022","journal-title":"Clin J Gastroenterol"},{"key":"2026092909590533400_bib50","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.2169\/internalmedicine.2870-23","article-title":"BRAF V600E-mutated colorectal neuroendocrine carcinoma effectively treated with a chemotherapy protocol for BRAF-mutated metastatic colorectal cancer","volume":"63","author":"Owaki","year":"2024","journal-title":"Intern Med"},{"key":"2026092909590533400_bib51","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics","volume":"2018","author":"Okamura","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2026092909590533400_bib52","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12022-024-09835-y","article-title":"Progression of low-grade neuroendocrine tumors (NET) to high-grade neoplasms harboring the NEC-like co-alteration of RB1 and TP53","volume":"35","author":"Joseph","year":"2024","journal-title":"Endocr Pathol"},{"key":"2026092909590533400_bib53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12022-024-09827-y","article-title":"Rapid evolution of metastases in patients with treated G3 neuroendocrine tumors associated with NEC-like transformation and TP53 mutation","volume":"35","author":"Kasajima","year":"2024","journal-title":"Endocr Pathol"},{"key":"2026092909590533400_bib54","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/path.6348","article-title":"The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation","volume":"264","author":"Backman","year":"2024","journal-title":"J Pathol"},{"key":"2026092909590533400_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100611","article-title":"Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics","volume":"7","author":"Schipper","year":"2022","journal-title":"ESMO Open"},{"key":"2026092909590533400_bib56","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Kr\u00e4mer","year":"2023","journal-title":"Ann Oncol"},{"key":"2026092909590533400_bib57","volume-title":"Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Occult Primary (Cancer of Unknown Primary [CUP])","author":"NCCN","year":"2024"},{"key":"2026092909590533400_bib58","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092909590533400_bib59","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092909590533400_bib60","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2018-02411","article-title":"Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092909590533400_bib61","doi-asserted-by":"crossref","first-page":"e1907","DOI":"10.1210\/clinem\/dgac019","article-title":"Surveillance improves outcomes for carriers of SDHB pathogenic variants: a multicenter study","volume":"107","author":"Davidoff","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092909590533400_bib62","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41431-023-01373-1","article-title":"Community concerns about genetic discrimination in life insurance persist in Australia: a survey of consumers offered genetic testing","volume":"32","author":"Tiller","year":"2024","journal-title":"Eur J Hum Genet"},{"key":"2026092909590533400_bib63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JGO.2015.002980","article-title":"Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs","volume":"3","author":"Singh","year":"2017","journal-title":"J Glob Oncol"},{"key":"2026092909590533400_bib64","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.18632\/oncotarget.27588","article-title":"Blood-based next-generation sequencing analysis of neuroendocrine neoplasms","volume":"11","author":"Zakka","year":"2020","journal-title":"Oncotarget"},{"key":"2026092909590533400_bib65","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1159\/000512502","article-title":"ctDNA in neuroendocrine carcinoma of gastroenteropancreatic origin or of unknown primary: the CIRCAN-NEC pilot study","volume":"111","author":"Gerard","year":"2021","journal-title":"Neuroendocrinology"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0225\/525852\/erc-26-0225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0225\/525852\/erc-26-0225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:59:30Z","timestamp":1790690370000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/9\/e260225\/78166\/Diagnostic-and-therapeutic-impact-of-genomic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-26-0225","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"e260225"}}